Established and Emerging Uses of Cytoprotection in Head and Neck Cancer
- 1 February 2006
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 132 (2) , 129-130
- https://doi.org/10.1001/archotol.132.2.129
Abstract
The delicate balance between the desired and undesired effects of medical treatment is particularly evident in oncology, in which the therapeutic window may beKeywords
This publication has 12 references indexed in Scilit:
- Feasibility and Efficacy of Subcutaneous Amifostine Therapy in Patients With Head and Neck Cancer Treated With Curative Accelerated Concomitant-Boost Radiation TherapyJAMA Otolaryngology–Head & Neck Surgery, 2006
- Palifermin for Oral Mucositis after Intensive Therapy for Hematologic CancersNew England Journal of Medicine, 2004
- A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparingSeminars in Oncology, 2004
- Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancerRadiotherapy and Oncology, 2004
- Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of HematologyJournal of Clinical Oncology, 2002
- 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical OncologyJournal of Clinical Oncology, 2002
- Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancerInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II StudyJournal of Clinical Oncology, 2000
- Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice GuidelinesJournal of Clinical Oncology, 1999
- Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.Journal of Clinical Oncology, 1996